Tiotropium Respimat ® Versus HandiHaler ® : Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials

Conclusion These findings support the use of the marketed once-daily dose of Respimat 5 μg for the maintenance treatment of patients with COPD. Funding Boehringer Ingelheim.

http://link.springer.com/10.1007/s12325-016-0322-9

Source: Advances in Therapy - March 27, 2016 Category: Drugs & Pharmacology Source Type: research